T. Christopher Mast

3.3k total citations · 1 hit paper
57 papers, 2.6k citations indexed

About

T. Christopher Mast is a scholar working on Infectious Diseases, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, T. Christopher Mast has authored 57 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Infectious Diseases, 17 papers in Cardiology and Cardiovascular Medicine and 16 papers in Epidemiology. Recurrent topics in T. Christopher Mast's work include Viral gastroenteritis research and epidemiology (31 papers), Viral Infections and Immunology Research (17 papers) and Hepatitis Viruses Studies and Epidemiology (16 papers). T. Christopher Mast is often cited by papers focused on Viral gastroenteritis research and epidemiology (31 papers), Viral Infections and Immunology Research (17 papers) and Hepatitis Viruses Studies and Epidemiology (16 papers). T. Christopher Mast collaborates with scholars based in United States, Hong Kong and Japan. T. Christopher Mast's co-authors include John D. Seeger, Swati B. Gupta, Florence T. Wang, Michelle G. Goveia, Jeanne Loughlin, Monica Reynolds, Brian R. Murphy, Joakim Dillner, Yi Pang and John T. Schiller and has published in prestigious journals such as Journal of Clinical Investigation, JNCI Journal of the National Cancer Institute and PEDIATRICS.

In The Last Decade

T. Christopher Mast

56 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

2016 295 citations T. Christopher Mast, Keith R. Jerome et al. profile →

Peers

Countries citing papers authored by T. Christopher Mast

Since Specialization

Citations

This map shows the geographic impact of T. Christopher Mast's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Christopher Mast with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Christopher Mast more than expected).

Fields of papers citing papers by T. Christopher Mast

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Christopher Mast. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Christopher Mast. The network helps show where T. Christopher Mast may publish in the future.

Co-authorship network of co-authors of T. Christopher Mast

This figure shows the co-authorship network connecting the top 25 collaborators of T. Christopher Mast. A scholar is included among the top collaborators of T. Christopher Mast based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Christopher Mast. T. Christopher Mast is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Benefit–risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373) 2024 ·Vaccine ·(unknown), T. Christopher Mast, Katherine R. Smith, Nicole L. Baker	1
2	CMV viral load kinetics as surrogate endpoints after allogeneic transplantation 2020 ·Journal of Clinical Investigation ·Elizabeth R. Duke, Brian D. Williamson, Bhavesh Borate, Jonathan L. Golob, (unknown), Terry Stevens‐Ayers, Meei‐Li Huang, Nicole Cossrow, Hong Wan, T. Christopher Mast, Morgan A. Marks, Mary E.D. Flowers, Keith R. Jerome, Lawrence Corey, Peter B. Gilbert, Joshua T. Schiffer, Michael Boeckh	40
3	Prediction of RecurrentClostridium DifficileInfection Using Comprehensive Electronic Medical Records in an Integrated Healthcare Delivery System 2017 ·Infection Control and Hospital Epidemiology ·Gabriel J. Escobar, Jennifer M. Baker, Patricia Kipnis, J Greene, T. Christopher Mast, Swati Gupta, Nicole Cossrow, Vinay Mehta, Vincent Liu, Erik R. Dubberke	35
4	Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach 2016 ·BMC Infectious Diseases ·Kamal Desai, Swati B. Gupta, Erik R. Dubberke, Vimalanand S. Prabhu, Chantelle Browne, T. Christopher Mast	132
5	Antibodies to Toxin B Are Protective AgainstClostridium difficileInfection Recurrence 2016 ·Clinical Infectious Diseases ·Swati B. Gupta, Vinay Mehta, Erik R. Dubberke, Xuemei Zhao, Marcus Dörr, Dalya Güriş, Deborah C. Molrine, Mark D. Leney, Mark A. Miller, (unknown), T. Christopher Mast	55
6	Evidence of Herd Immunity and Sustained Impact of Rotavirus Vaccination on the Reduction of Rotavirus-Related Medical Encounters Among Infants from 2006 through 2011 in the United States 2015 ·The Pediatric Infectious Disease Journal ·T. Christopher Mast, Florence T. Wang, (unknown), John D. Seeger	27
7	Accuracy of administrative claims data to identify dose specific rotavirus vaccination information: Implications for studies of vaccine safety 2015 ·Vaccine ·Scott Quinlan, Stephan Lanes, Crystal N. Holick, T. Christopher Mast	1
8	Assessing bias in administrative database studies of RotaTeq vaccine completion due to exclusion of subjects with incomplete follow-up 2015 ·Emerging Themes in Epidemiology ·Stephan Lanes, Scott Quinlan, T. Christopher Mast, Sander Greenland, Crystal N. Holick	7
9	Adaptation of a previously validated vaccination report card for use in adult vaccine clinical trials to align with the 2007 FDA Toxicity Grading Scale Guidance 2012 ·Human Vaccines & Immunotherapeutics ·Josephine M. Norquist, (unknown), (unknown), T. Christopher Mast, Kai‐Li Liaw, Michael Robertson, Barbara J. Evans, David Gutsch, Patricia Saddier	16
10	Effectiveness of an Incomplete RotaTeq (RV5) Vaccination Regimen in Preventing Rotavirus Gastroenteritis in the United States 2012 ·The Pediatric Infectious Disease Journal ·Florence T. Wang, T. Christopher Mast, Roberta Glass, Jeanne Loughlin, John D. Seeger	25
11	Long-Term Safety from the Raltegravir Clinical Development Program 2011 ·Current HIV Research ·Hedy Teppler, Deborah D. Brown, Randi Y. Leavitt, Peter Sklar, Hong Wan, Xia Xu, Fabio Lievano, (unknown), T. Christopher Mast, Bach‐Yen Nguyen	30
12	Incidence of Intussusception Among Infants in a Large Commercially Insured Population in the United States 2011 ·The Pediatric Infectious Disease Journal ·Patricia Mona Eng, T. Christopher Mast, Jeanne Loughlin, C. Robin Clifford, (unknown), John D. Seeger	17
13	Estimating the Rotavirus Hospitalization Disease Burden and Trends, Using Capture-recapture Methods 2010 ·The Pediatric Infectious Disease Journal ·Mary Allen Staat, (unknown), Stephanie Donauer, Daniel C. Payne, Joseph Bresee, T. Christopher Mast, Aaron T. Curns, Margaret M. Cortese, Beverly L. Connelly, Monica McNeal, Richard L. Ward, David I. Bernstein, Umesh D. Parashar, Shelia Salisbury	15
14	The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions 2010 ·Journal of Psychosomatic Obstetrics & Gynecology ·Kung‐Liahng Wang, Cherng‐Jye Jeng, Yuh‐Cheng Yang, Chi‐An Chen, Wen‐Fang Cheng, Tze-Chien Chen, T. Christopher Mast, (unknown), Chang‐Yao Hsieh	47
15	Burden of Childhood Rotavirus Disease on Health Systems in the United States 2010 ·The Pediatric Infectious Disease Journal ·T. Christopher Mast, Emmanuel B. Walter, (unknown), (unknown), Daniel J. DiStefano, (unknown), Walter L. Straus, Mary Allen Staat	39
16	US Post-Licensure Active Surveillance Safety Study of RotaTeq™, Oral Pentavalent Rotavirus Vaccine (RV5) 2009 ·T. Christopher Mast	1
17	The impact of rotavirus gastroenteritis on the family 2009 ·BMC Pediatrics ·T. Christopher Mast, Carla DeMuro‐Mercon, (unknown), (unknown), Emmanuel B. Walter	55
18	Post-Licensure Effectiveness of RotaTeq ® in Preventing Gastroenteritis 2008 ·46th Annual Meeting ·T. Christopher Mast	10
19	Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine 2001 ·JNCI Journal of the National Cancer Institute ·Clayton Harro, Yi Pang, Richard B.S. Roden, Allan Hildesheim, (unknown), Monica Reynolds, T. Christopher Mast, Robin A. Robinson, Brian R. Murphy, Ruth A. Karron, Joakim Dillner, John T. Schiller, D R Lowy	454
20	Suppression of HIV-1 Reverse Transcriptase Activity by Mycoplasma Contamination of Cell Cultures 1990 ·AIDS Research and Human Retroviruses ·M. B. Vasudevachari, T. Christopher Mast, Norman P. Salzman	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact